From disease basics to insightful analysis of market dynamics, Heart Failure | Disease Landscape & Forecast | G7 provides comprehensive disease coverage addressing critical aspects of the heart failure pharmaceutical market based on detailed primary and secondary market research. Content pillars include a summary of disease etiology, pathophysiology, and drug targets; annualized epidemiological projections, including estimates of diagnosis and/or drug-treatment; a deep examination of current therapies and medical practice; a review of top unmet needs; a thorough pipeline assessment, including launch timing, positioning, and peak sales of key late-phase drugs; a topline review of pertinent market access themes; and an epidemiology-based, bottom-up market forecast with supporting tables, figures, and methods.
Key questions answered in this content include:
- How large is the treatable heart failure population and how will diagnosis/drug-treatment rates change over time?
- What is the current state of treatment in heart failure? Which are the most important drugs and why? What are interviewed experts’ insights on current treatment options? What clinical needs remain unfulfilled?
- What pipeline products are most promising, and what sales/uptake could they secure in heart failure? What therapies of note are progressing in earlier phases?
- What are the drivers and constraints in the heart failure market, and how will the market evolve over the forecast period?